ADT intensification may not improve prostate cancer survival. Explore real-world findings and key risk factors. Read more.
Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.
Hosted on MSN
Expert Q&A: Your Questions About the Cost of ADT for Advanced Prostate Cancer, Answered
Androgen deprivation therapy (ADT), also called hormone therapy, is a common treatment for metastatic prostate cancer. It works by starving the cancer of testosterone, which fuels the tumors growth.
New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...
This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...
In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.
A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first ...
Patients who received ADT for 3 months or 9 months had worse overall survival than those treated for 36 months. For men with prostate cancer treated with definitive radiotherapy, the benefit derived ...
A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...
In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer Alliance A222001: Oxybutynin Versus Placebo for ...
Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial of men with prostate cancer. Significantly more coronary artery plaque ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results